A Phase IIb/III trial with infants entering their first respiratory syncytial virus (RSV) season met its primary endpoints.

An 800% increase in licensing deal values indicates growing confidence in mRNA technology, but some vaccine producers are ...

The expanded approval intensifies the rivalry with Jazz Pharmaceuticals, which has previously attempted to block Lumryz’s ...

TheracosBio has entered a partnership with BAMCO Africa to deliver BRENZAVVY (bexagliflozin) to patients in sub-Saharan ...

Sanofi and Orano Group subsidiary Orano Med have announced a partnership to enhance the development of next-generation RLTs.

With less than three weeks until Americans cast their vote, what would healthcare look under a Harris or Trump administration ...

A potential three-year framework agreement between the Greek government and the pharmaceutical industry, starting at the ...

In the US, diagnosed prevalence is anticipated to increase across all opioid addiction patient segments. Credit: Iryna Imago ...

The US FDA has approved AbbVie's VYALEV to treat motor fluctuations in adults with advanced Parkinson's disease (PD).

Lexicon Pharmaceuticals has entered a licensing agreement with Viatris, granting the latter exclusive rights to commercialise ...

After a hearing held on 25 September 2024, the European Patent Office (EPO) affirmed bit.bio’s claim against an anonymous ...

Synedgen has announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to develop its ...